期刊
JOURNAL OF CONTROLLED RELEASE
卷 330, 期 -, 页码 101-110出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2020.12.017
关键词
Prostate cancer; Prostate-specific membrane antigen; Active targeting; Exosome mimetics
资金
- Rosetrees Trust studentship 2016-2019 [M542]
- Prostate Cancer UK [CDF12-002]
- Engineering and Physical Sciences Research Council (EPSRC) [EP/M008657/1]
- EPSRC [EP/M008657/1] Funding Source: UKRI
The engineered anti-PSMA peptide-targeted EMs showed increased cellular internalization in PSMA positive PC cell lines and higher tumor targeting ability in vivo, indicating their potential as a promising drug delivery system for advanced prostate cancer.
The present work describes the engineering of anti-PSMA peptide-decorated exosome mimetics (EMs) targeting advanced prostate cancer (PC). The targeted EMs were produced from anti-PSMA peptide, WQPDTAHHWATL, expressing U937 monoblastic cells, followed by successive extrusion cycles. The engineered EMs were nanosized, produced at a high yield, and displayed the anti-PSMA peptide, exosomal markers and monocytes proteins on their surface. As anticipated, PSMA-EMs showed increased cellular internalization in PSMA positive PC cell lines (LNCaP and C4-2B), compared to unmodified EMs. Most importantly, higher tumour targeting was observed in solid C4-2B tumours, following intravenous administration, confirming their targeting ability in vivo. Overall, our study indicates that the engineered anti-PSMA peptide-targeted EMs can be a promising drug delivery system for advanced PC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据